dc.contributor.author | McCormack, T. | |
dc.contributor.author | Harvey, P. | |
dc.contributor.author | Gaunt, R. | |
dc.contributor.author | Allgar, V. | |
dc.contributor.author | Chipperfield, R. | |
dc.contributor.author | Robinson, P. | |
dc.date.accessioned | 2012-04-12T14:58:11Z | |
dc.date.available | 2012-04-12T14:58:11Z | |
dc.date.issued | 2010-07 | |
dc.identifier.citation | McCormack , T , Harvey , P , Gaunt , R , Allgar , V , Chipperfield , R & Robinson , P 2010 , ' Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE) : randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets ' , International Journal of Clinical Practice , vol. 64 , no. 8 , pp. 1052-1061 . https://doi.org/10.1111/j.1742-1241.2010.02429.x | |
dc.identifier.issn | 1368-5031 | |
dc.identifier.other | PURE: 780409 | |
dc.identifier.other | PURE UUID: d8aef861-5a49-4c7a-8382-17883bf43a07 | |
dc.identifier.other | WOS: 000278920800014 | |
dc.identifier.other | Scopus: 77953835588 | |
dc.identifier.uri | http://hdl.handle.net/2299/8313 | |
dc.description.abstract | The aim of this study was to compare ezetimibe/simvastatin combination therapy with intensified statin monotherapy as alternative treatment strategies to achieve the Joint British Societies (JBS)-2 and National Institute for Health and Clinical Excellence low-density-lipoprotein cholesterol (LDL-C) target of < 2 mmol/l for secondary prevention or JBS-2 LDL-C target of < 2 mmol/l for primary prevention in high-risk patients who have failed to reach target with simvastatin 40 mg. Methods: This is a prospective, double-blind study conducted in 34 UK primary care centres; 1748 patients with established cardiovascular disease (CVD), diabetes or high risk of CVD who had been taking simvastatin 40 mg for >= 6 weeks were screened and 786 (45%) with fasting LDL-C >= 2.0 mmol/l (and < 4.2 mmol/l) at screening and after a further 6-week run-in period on simvastatin 40 mg were randomised to ezetimibe/simvastatin 10/40 mg (as a combination tablet; n = 261), atorvastatin 40 mg (n = 263) or rosuvastatin 5 mg (n = 73) or 10 mg (n = 189) once daily for 6 weeks. Rosuvastatin dose was based on UK prescribing instructions. The primary outcome measure was the proportion of patients achieving LDL-C < 2 mmol/l at the end of the study. Results: The percentage of patients (adjusted for baseline differences) achieving LDL-C < 2 mmol/l was 69.4% with ezetimibe/simvastatin 10/40 mg, compared with 33.5% for atorvastatin 40 mg [odds ratio 4.5 (95% CI: 3.0-6.8); p < 0.001] and 14.3% for rosuvastatin 5 or 10 mg [odds ratio 13.6 (95% CI: 8.6-21.6); p < 0.001]. Similar results were observed for achievement of total cholesterol < 4.0 mmol/l. All study treatments were well tolerated. Conclusion: Approximately 45% of patients screened had not achieved LDL-C < 2 mmol/l after >= 12 weeks of treatment with simvastatin 40 mg. In this group, treatment with ezetimibe/simvastatin 10/40 mg achieved target LDL-C levels in a significantly higher proportion of patients during a 6-week period than switching to either atorvastatin 40 mg or rosuvastatin 5-10 mg. | en |
dc.format.extent | 10 | |
dc.language.iso | eng | |
dc.relation.ispartof | International Journal of Clinical Practice | |
dc.subject | LIPID-ALTERING EFFICACY | |
dc.subject | STATIN THERAPY | |
dc.subject | SIMVASTATIN | |
dc.subject | EZETIMIBE | |
dc.subject | METAANALYSIS | |
dc.subject | MONOTHERAPY | |
dc.subject | DISEASE | |
dc.subject | DESIGN | |
dc.subject | MG | |
dc.title | Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE) : randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets | en |
dc.contributor.institution | Department of Pharmacy | |
dc.description.status | Peer reviewed | |
rioxxterms.versionofrecord | https://doi.org/10.1111/j.1742-1241.2010.02429.x | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |